The 10 B isotope has been almost exclusively used in the neutron-capture radiation therapy (NCT) of cancer for decades. We have identified two other nuclides suitable for the radiotherapy, which have ca.10 times larger cross section of absorption for neutrons and emit heavy charged particles. This would provide several key advantages for potential NCT, such as the possibility to use either a lower nuclide concentration in the target tissues, or a lower neutron irradiation flux.
INTRODUCTION
The use of the ionizing radiation in treatment of cancer has a long and successful history [1] , and it is one of the most remarkable examples of direct medical outreach as results of modern physics. Energetic photons, leptons or heavy charged particles can ionize biological matter creating lethal damages to living cells through the direct disintegration of important biomolecules (like DNA or RNA) and by creating chemically active radicals destroying cell's biochemistry [2] . The radiation therapy is a valid alternative and a complementary treatment to the surgery and to the chemotherapy in oncology practices, used in more than 50% of patients with cancer [3] .
One of the issues in the radiation therapy is to deliver the ionization selectively into a spatially localized region occupied by the tumor, ranging from few millimeters to several centimeters in size. The surrounding healthy tissues must receive as small radiation damage as possible to avoid side effects [3] . The ionizing radiation can be delivered from outside the patient, -a method known as external-beam radiation therapy (EBRT). Heavy charged particles (protons, accelerated nuclei) have an advantage over leptons and photons due to relatively small range straggling and to the sharp Bragg peak in the energy loss vs the path length curve, located in the end of particle's range in the tissue [4] [5] [6] . Therefore, the radiation damage to the tissues may be localized inside the tumor. The heavy particles, however, have shorter ranges in matter than light particles and photons at the same kinetic energy. Therefore, to access tumors deep in the body one needs to accelerate the particles up to the energies of few hundreds MeV/u, to deliver and to focus the beam onto the target in human body. This makes the infrastructure for the heavy particle radiation therapy very complex, expensive, and limited to large medical/research centers, while a much cheaper gamma-ray radiation therapy has come to many common hospitals [5, 7] .
A way to overcome the problem of delivery of fast particles into tumor is to put the radiation source directly into the cancerous tissue. This idea is realized by physically placing a radioactive nuclide enclosed in a protective capsule or as a wire inside (or next to) the target tissues (brachytherapy), what often requires surgery [8] . Alternatively, one may use radioactive nuclides bound into radiopharmaceuticals selectively transported into the target tissues [9] . The spontaneous decay of a radioisotope nucleus may release up to several tens of MeV, converted into the kinetic energy of charged product particles and deposited into the ionization in the range within less than a millimeter around the decaying nucleus. The radionuclide therapy, therefore, replaces the problem of kinematic delivery of the ionizing particle into the target tissue in EBRT with the problem of selective accumulation of radiopharmaceuticals . The radionuclide therapy also brings a new issue -the problematic temporal control. The timescales of the accumulation and of the excretion of radiopharmaceuticals (which are regulated by the metabolism and are difficult to control) should be in due relation to the lifetime of the isotope, so that to maximize the part of the nuclei decayed in the tumor and not on their way into or out of the target. It is not possible to initiate and to stop the therapy on an arbitrary moment. Moreover, many radionuclides as well as their products are heavy elements, which are known for their toxicity and problematic excretion [3] .
In the neutron capture radiation therapy (NCT) the active isotope undergoes induced radioactive decay following the capture of a neutron. This method combines the local energy deposition property of the radionuclide therapy and a good temporal control of the beam-particle radiation therapy, as the neutron flux may be switched on and off quickly. (a) (b) Figure 1 . Schematic diagrams of the 7 Be (a) and of the 22 Na (b) spontaneous decay, the data are from [20] and [21] , respectively.
As the decay rate depends on the electronic density at the nucleus, 7 Be has been used in the studies of the effect of the chemical environment onto the nuclear processes [22] [23] [24] .
Besides, and even more importantly, 7 Be is assumed to play a key role in the lithium yield of the big bang nucleosynthesis for standard cosmology via the neutron absorption reaction [27] and also is used in the positron emission tomography (PET).
In Table I , we summarize the neutron capture properties of the two radionuclides and compare them with the properties of 10 B. The neutron capture reactions pass via an inter- σ nα (100) = 0.0611 σ np (100) = 0.7 σ np (100) = 0.5 energy range, E n < 100 eV, [26] 
NEUTRON CAPTURE ENERGY DEPOSITION
For more direct comparison of the BNCT with potential BeNCT and NaNCT, we estimate the energy deposition after neutron capture in water, see Table II , considering only the predominant reaction channels. The γ-radiation emitting in the predominant channels for BNCT and NaNCT (Table I) To relate the radiation doses in water to the biological context, we will consider the Table II 
OPEN PROBLEMS
There are also new challenges on the way of 7 Be and 22 Na to the successful NCT.
22 Na is used for PET and it is already a commercial product. On the 10-1000 ng scale necessary for experimental studies, 7 Be may be produced as a byproduct on existing acceleratorbased neutron sources utilizing, e.g., the proton induced spallation reaction on 16 per second) of initial mass M, after time t reads,
where A m = ln(2)N A /(µT 1/2 ) is the nuclide-mass-specific activity, µ is the molar mass. Table III shows that the mass-specific activity for the 7 Be is the largest despite the half-life for 131 I is shorter; apparently, it is due to the almost 20 times larger isotope mass for the iodine.
To characterize the external (personnel and environmental) radiation risk of a radionuclide, one ordinary calculates the absorbed radiation dose rate at a certain distance d from a point-like source of activity A. The distance is typically large enough (e.g., 1 m) so that all the β radiation is absorbed well before d, and only γ-radiation contributes to the ionization.
The external γ-radiation dose rate reads, .
The calculated external dose rate per 1 µg of nuclide,Ḋ int , is reported in Table III For the radiation therapy of thyroid cancer one uses the amount of 131 I equivalent to the activity ranging from 0.2 to more than 50 GBq [41] . As 4.6 GBq corresponds to 1 µg (see Table III 
